
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
	Net Unrealized Gains/(Losses)						Benefit Plans
(MILLIONS OF DOLLARS)	Foreign Currency Translation Adjustments		Derivative Financial Instruments		Available-For-Sale Securities		Actuarial Gains/(Losses)		Prior Service (Costs)/Credits and Other		Accumulated Other Comprehensive Income/(Loss)
Balance, December 31, 2019	$	(5,952)	$	20	$	(35)	$	(6,257)	$	584	$	(11,640)
Other comprehensive income/(loss)(a)	249		(546)		179		(817)		(102)		(1,036)

Balance, September 27, 2020	$	(5,703)	$	(526)	$	144	$	(7,074)	$	482	$	(12,676)

(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $9 million loss for the first nine months of 2020. Foreign currency translation adjustments primarily include gains from the strengthening of certain major currencies against the U.S. dollar, partially offset by net after-tax losses related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in GSK Consumer Healthcare joint venture (see Note 2B). The actuarial gains/(losses) activity mainly reflects interim U.S. Pfizer Consolidated Pension remeasurements, which resulted in an increase of $1.2 billion in the pension plan liability, primarily due to a reduction in the discount rate since December 31, 2019.